Vir Biotechnology Stock Today
| VIR Stock | USD 8.25 0.11 1.32% |
Performance0 of 100
| Odds Of DistressLess than 34
|
Vir Biotechnology is selling at 8.25 as of the 18th of April 2024; that is -1.32 percent decrease since the beginning of the trading day. The stock's lowest day price was 8.21. Vir Biotechnology has about a 34 percent probability of financial distress in the next few years of operation and has generated negative returns over the last 90 days. Equity ratings for Vir Biotechnology are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 19th of March 2024 and ending today, the 18th of April 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 11th of October 2019 | Category Healthcare | Classification Health Care |
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California. Vir Biotechnology operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 135.03 M outstanding shares of which 4.96 M shares are at this time shorted by investors with about 5.16 days to cover. More on Vir Biotechnology
Moving together with Vir Stock
| 0.66 | JNJ | Johnson Johnson Financial Report 18th of July 2024 | PairCorr |
| 0.68 | GRTX | Galera Therapeutics Financial Report 9th of May 2024 | PairCorr |
Moving against Vir Stock
| 0.6 | MRKR | Marker Therapeutics | PairCorr |
| 0.42 | LPTX | Leap Therapeutics Financial Report 20th of May 2024 | PairCorr |
Follow Valuation Options Odds of Bankruptcy
Financial Report 2nd of May 2024
Vir Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Vir Biotechnology's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Vir Biotechnology or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| CEO Director | MBA MSc | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Old Names | [Experion Holdings Ltd, VIR] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, SP Small-Cap 600, NASDAQ Biotechnology, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation Analysts covering Vir Biotechnology report their recommendations after researching Vir Biotechnology's financial statements, talking to executives and customers, or listening in on Vir Biotechnology's conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Vir Biotechnology. The Vir consensus assessment is calculated by taking the average forecast from all of the analysts covering Vir Biotechnology. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Financial Strength Based on the key measurements obtained from Vir Biotechnology's financial statements, Vir Biotechnology is not in a good financial situation at this time. It has a very high odds of going through financial crisis in May. Financial strength of Vir Biotechnology is based on its profitability, leverage, liquidity, source of funds, and operating efficiency.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vir Biotechnology's financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Vir Biotechnology's success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Vir Biotechnology's financial leverage. It provides some insight into what part of Vir Biotechnology's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vir Biotechnology (VIR) is traded on NASDAQ Exchange in USA. It is located in 1800 Owens Street, San Francisco, CA, United States, 94158 and employs 587 people. Vir Biotechnology is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a total capitalization of 1.13 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Vir Biotechnology's market, we take the total number of its shares issued and multiply it by Vir Biotechnology's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Vir Biotechnology runs under Biotechnology sector within Health Care industry. The entity has 135.03 M outstanding shares of which 4.96 M shares are at this time shorted by investors with about 5.16 days to cover.
Vir Biotechnology has about 2.2 B in cash with (778.78 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 16.55, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Vir Biotechnology Probability Of Bankruptcy
Ownership AllocationVir Biotechnology maintains a total of 135.03 Million outstanding shares. The majority of Vir Biotechnology outstanding shares are owned by institutional holders. These institutional investors are usually referred to as non-private investors looking to take positions in Vir Biotechnology to benefit from reduced commissions. Consequently, institutions are subject to a different set of regulations than regular investors in Vir Biotechnology. Please pay attention to any change in the institutional holdings of Vir Biotechnology as this could imply that something significant has changed or is about to change at the company. Remember, it does not matter who owns the company or if the company is currently losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.
Check Vir Ownership Details
Vir Stock Price Odds Analysis
In regard to a normal probability distribution, the odds of Vir Biotechnology jumping above the current price in 90 days from now is about 98.0%. The Vir Biotechnology probability density function shows the probability of Vir Biotechnology stock to fall within a particular range of prices over 90 days. Considering the 90-day investment horizon the stock has a beta coefficient of 2.3017. This entails as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Vir Biotechnology will likely underperform. Additionally, vir Biotechnology has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the NYSE Composite.
Based on a normal probability distribution, the odds of Vir Biotechnology to move above the current price in 90 days from now is about 98.0 (This Vir Biotechnology probability density function shows the probability of Vir Stock to fall within a particular range of prices over 90 days) .
Vir Stock Institutional Holders
Institutional Holdings refers to the ownership stake in Vir Biotechnology that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Vir Biotechnology's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Vir Biotechnology's value.| Instituion | Recorded On | Shares | |
| Goldman Sachs Group Inc | 2023-12-31 | 1.2 M | |
| Northern Trust Corp | 2023-12-31 | 937.3 K | |
| D. E. Shaw & Co Lp | 2023-09-30 | 880.2 K | |
| Charles Schwab Investment Management Inc | 2023-12-31 | 753.1 K | |
| Bank Of New York Mellon Corp | 2023-12-31 | 720.9 K | |
| Ubs Group Ag | 2023-12-31 | 526.2 K | |
| Principal Financial Group Inc | 2023-12-31 | 507.6 K | |
| Dimensional Fund Advisors, Inc. | 2023-12-31 | 468.3 K | |
| Prudential Financial Inc | 465.5 K | ||
| Blackrock Inc | 2023-12-31 | 16.9 M | |
| Sb Investment Advisers (uk) Ltd | 2023-12-31 | 16.7 M |
Vir Biotechnology Historical Income Statement
Vir Biotechnology Income Statement is one of the three primary financial statements used for reporting Vir's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Vir Biotechnology revenue and expense. Vir Biotechnology Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At this time, Vir Biotechnology's Net Interest Income is relatively stable compared to the past year. As of 04/18/2024, Interest Income is likely to grow to about 86.5 M, while Selling General Administrative is likely to drop slightly above 103 M. View More FundamentalsVir Stock Against Markets
Picking the right benchmark for Vir Biotechnology stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Vir Biotechnology stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Vir Biotechnology is critical whether you are bullish or bearish towards Vir Biotechnology at a given time. Please also check how Vir Biotechnology's historical prices are related to one of the top price index indicators.
Be your own money manager
Our tools can tell you how much better you can do entering a position in Vir Biotechnology without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Companies Directory Now
Companies DirectoryEvaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals |
| All Next | Launch Module |
Vir Biotechnology Corporate Management
Elected by the shareholders, the Vir Biotechnology's board of directors comprises two types of representatives: Vir Biotechnology inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Vir. The board's role is to monitor Vir Biotechnology's management team and ensure that shareholders' interests are well served. Vir Biotechnology's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Vir Biotechnology's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Vanina JD | General VP | Profile | |
| Klaus Frueh | CoFounder Advisor | Profile | |
| Lawrence MD | CoFounder Advisor | Profile | |
| Johanna FriedlNaderer | Ex COO | Profile | |
| George Scangos | CEO Pres | Profile | |
| Louis MD | CoFounder Advisor | Profile |
How to buy Vir Stock?
Before investing in Vir Biotechnology, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in Vir Biotechnology. To buy Vir Biotechnology stock, you can follow these steps:- Choose a brokerage firm: You need to select a brokerage firm to buy shares of Vir Biotechnology. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
- Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
- Fund your account: You will need to deposit funds into your brokerage account to purchase Vir Biotechnology stock. You can do this by transferring funds from your bank account or other investment accounts.
- Place your order: Once you have located Vir Biotechnology stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
- Monitor your investment: After you have purchased Vir Biotechnology stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as Vir Biotechnology, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy Vir Stock please use our How to Invest in Vir Biotechnology guide.
Already Invested in Vir Biotechnology?
The danger of trading Vir Biotechnology is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Vir Biotechnology is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Vir Biotechnology. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Vir Biotechnology is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Vir Biotechnology is a strong investment it is important to analyze Vir Biotechnology's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Vir Biotechnology's future performance. For an informed investment choice regarding Vir Stock, refer to the following important reports: Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vir Biotechnology. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in Vir Stock, please use our How to Invest in Vir Biotechnology guide.You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Complementary Tools for Vir Stock analysis
When running Vir Biotechnology's price analysis, check to measure Vir Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vir Biotechnology is operating at the current time. Most of Vir Biotechnology's value examination focuses on studying past and present price action to predict the probability of Vir Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vir Biotechnology's price. Additionally, you may evaluate how the addition of Vir Biotechnology to your portfolios can decrease your overall portfolio volatility.
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance |
Is Vir Biotechnology's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Vir Biotechnology. If investors know Vir will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Vir Biotechnology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.585 | Earnings Share (4.59) | Revenue Per Share 0.643 | Quarterly Revenue Growth (0.66) | Return On Assets (0.17) |
The market value of Vir Biotechnology is measured differently than its book value, which is the value of Vir that is recorded on the company's balance sheet. Investors also form their own opinion of Vir Biotechnology's value that differs from its market value or its book value, called intrinsic value, which is Vir Biotechnology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Vir Biotechnology's market value can be influenced by many factors that don't directly affect Vir Biotechnology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Vir Biotechnology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Vir Biotechnology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Vir Biotechnology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.